Cullinan Associates Inc. Sells 6,010 Shares of Johnson & Johnson $JNJ

Key Points

• Cullinan Associates reduced its Johnson & Johnson position by 3.3%, selling 6,010 shares and retaining 177,028 shares valued at approximately $44.96 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly expectations with EPS of $2.90 and revenue of $25.31 billion, while revenue rose 6.6% year over year. The company maintained 2026 EPS guidance of $11.60–$11.75 and declared a $1.34 quarterly dividend, yielding about 2.0% annually.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $272.83. However, shares trade near their 52-week high at roughly 31 times earnings, and recent insider selling may temper near-term upside.

Cullinan Associates Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 177,028 shares of the company's stock after selling 6,010 shares during the quarter. Johnson & Johnson comprises about 3.4% of Cullinan Associates Inc.'s holdings, making the stock its 5th largest position. Cullinan Associates Inc.'s holdings in Johnson & Johnson were worth $44,960,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of JNJ. Blueline Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth about $25,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after purchasing an additional 142 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $37,000. Finally, Matrix Trust Co increased its holdings in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock opened at $267.20 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business has a 50-day simple moving average of $262.88 and a two-hundred day simple moving average of $245.62. The company has a market capitalization of $643.93 billion, a P/E ratio of 30.96, a price-to-earnings-growth ratio of 2.57 and a beta of 0.24. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is 62.11%.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Guggenheim increased their price target on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research note on Monday, August 3rd. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $272.83.

Insider Activity

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by company insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the Wells Fargo Healthcare Conference, Johnson & Johnson highlighted growth opportunities in MedTech, with cardiovascular products taking center stage. Management’s focus on high-end, innovative devices supports the company’s longer-term growth outlook. Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
• Positive Sentiment: JNJ is preparing to present 24 abstracts at Psych Congress 2026, including pivotal Phase 3 CAPLYTA data in bipolar mania and new SPRAVATO analyses. The data could strengthen confidence in the company’s neuropsychiatry pipeline and future pharmaceutical growth. Johnson & Johnson Neuropsychiatry Data
• Positive Sentiment: Jim Cramer characterized the recent weakness as a buying opportunity, reinforcing the view that JNJ’s defensive profile, diversified healthcare operations, and dividend appeal may attract investors during market uncertainty. Cramer Says It’s Time to Buy the Dip on JNJ
• Neutral Sentiment: Analysts and market commentary continue to view JNJ as a defensive stock ahead of inflation data and the Federal Reserve’s next rate decision. That positioning may support demand, but macroeconomic uncertainty is also increasing day-to-day volatility. Defensive Stocks Ahead of CPI and the Fed
• Negative Sentiment: JNJ recently declined more than the broader market, suggesting profit-taking or increased sensitivity to market-wide selling. With shares near their 52-week high and trading at roughly 31 times earnings, valuation may be limiting near-term upside despite solid earnings and full-year EPS guidance. Johnson & Johnson Sees a More Significant Dip Than the Broader Market

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.